Photo of Laurie-Anne Grelier

Laurie-Anne Grelier

Laurie-Anne Grelier assists global companies, especially Asian multinationals, with navigating the competition law aspects of their activities and investments in Europe. Laurie-Anne cumulates more than 10 years of experience advising these companies on complex, high-stake European competition law issues, including antitrust and cartel investigations, the clearance of mergers and other transactions, the structuring of licensing, distribution, collaborative and other commercial arrangements, issues related to abuse of dominant position, and the structuring of compliance programs.

Laurie-Anne further represents these companies in litigation before the European Courts, whether in their challenges of regulatory decisions or in the defense of multi-million private antitrust claims.

Laurie-Anne also advises Asian companies on the application of new regulations in the technology sector, such as the EU Digital Markets Act as well as on state aid and foreign direct investment.

Laurie-Anne has elementary proficiency in Korean.

Contact:Read more about Laurie-Anne GrelierEmail

The times when private antitrust damages claims were not a serious risk in the European Union are gone.  The European Commission and national competition authorities are actively promoting follow-on damages claims by private plaintiffs, and national health authorities are themselves bringing huge claims for damages arising from anticompetitive practices.

The following are examples of recent claims:

  • Servier.  In parallel with the EU Commission’s investigation into Servier’s reverse payment patent settlements concerning perindopril, a number of UK health authorities have filed damage claims seeking more than ₤230 million in damages from Servier.
  • Reckitt Benckiser. In connection with the OFT’s 2010 decision imposing a ₤10.2 million fine on Reckitt Benckiser for practices related to Gaviscon Original Liquid, the UK health authorities and a generic competitor have brought follow-on damage claims seeking approximately £89 million from Reckitt Benckiser.
    Continue Reading Private Antitrust Damages Claims in the Pharmaceuticals Sector: Gaining Momentum